文献速递肝病消化道肿瘤与早癌

肝细胞癌患者甲胎蛋白从>1000降至<500 ng/mL可改善移植后结局

Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.
PubMed 文献 · Hepatology · 2019-02-10

该研究利用美国器官共享网络数据库,纳入2005年1月至2015年9月间移植前至少一次甲胎蛋白>1000 ng/mL的407例肝细胞癌肝移植患者,评估移植前甲胎蛋白降至不同阈值对生存和复发的影响,结果显示降至<500 ng/mL者移植后结局显著改善,验证了新实施的国家政策。

要点

  • 移植前甲胎蛋白>1000 ng/mL者5年移植后生存率为48.8%,降至101-499 ng/mL者为67.0%,降至≤100 ng/mL者为88.4%。
  • 移植前甲胎蛋白>1000 ng/mL者5年肝细胞癌复发概率为35.0%,降至101-499 ng/mL者为13.3%,降至≤100 ng/mL者为7.2%。
  • 多因素分析显示,甲胎蛋白降至101-499 ng/mL与移植后死亡风险降低>2倍相关(P=0.01),与肝细胞癌复发风险降低近3倍相关(P=0.02)。

核心结论

  • 研究结果表明,将肝移植限制于甲胎蛋白从>1000降至<500 ng/mL的患者可显著改善移植后结局,验证了近期实施的国家政策。

研究设计与样本

  • 利用美国器官共享网络数据库,识别2005年1月至2015年9月间接受移植且移植前至少一次甲胎蛋白>1000 ng/mL的407例患者。

主要发现

  • 移植前最后一次甲胎蛋白测量值:>1000 ng/mL者占72.0%,从>1000降至101-499 ng/mL者占9.6%,降至≤100 ng/mL者占14.3%。
  • 移植时甲胎蛋白>1000 ng/mL者中45.4%未接受局部区域治疗,而移植时甲胎蛋白101-499 ng/mL者中为12.8%,≤100 ng/mL者中为10.3%(P<0.001)。
  • 移植后5年生存率:移植时甲胎蛋白>1000 ng/mL者为48.8%,降至101-499 ng/mL者为67.0%(P<0.001),降至≤100 ng/mL者为88.4%(P<0.001)。
  • 移植后5年肝细胞癌复发概率:移植时甲胎蛋白>1000 ng/mL者为35.0%,101-499 ng/mL者为13.3%,≤100 ng/mL者为7.2%(P<0.001)。
  • 多因素分析显示,与移植时甲胎蛋白>1000 ng/mL相比,降至101-499 ng/mL与移植后死亡风险降低>2倍相关(P=0.01),与肝细胞癌复发风险降低近3倍相关(P=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High alpha-fetoprotein (AFP) > 1,000 ng/mL is associated with poor outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). A new national policy has been implemented for AFP > 1,000 ng/mL requiring a decrease to < 500 ng/mL before LT, but there is a paucity of data on the optimal AFP threshold before LT. We aimed to evaluate the effects of a reduction in AFP from > 1,000 ng/mL to different AFP thresholds before LT on survival and HCC recurrence after LT using the United Network for Organ Sharing database. We identified 407 patients who underwent transplant between January 2005 and September 2015 and who had AFP > 1,000 ng/mL at least once before LT. The last AFP measurement before LT was > 1,000 ng/mL in 72.0%, decreased from > 1,000 to 101-499 ng/mL in 9.6%, and decreased to ≤ 100 ng/mL in 14.3%. Local-regional therapy was not performed in 45.4% of patients with AFP > 1,000 ng/mL at LT versus 12.8% of those with AFP of 101-499 ng/mL and 10.3% of those with AFP ≤ 100 ng/mL at LT (P < 0.001). Kaplan-Meier 5-year post-LT survival for those with AFP > 1,000 ng/mL at LT was 48.8% versus 67.0% for those with a decrease in AFP to 101-499 ng/mL (P < 0.001) and 88.4% for those with AFP ≤ 100 ng/mL at LT (P < 0.001). HCC recurrence probability at 5 years was 35.0% for patients with AFP > 1,000 ng/mL versus 13.3% for patients with AFP of 101-499 ng/mL and 7.2% for patients with AFP ≤ 100 ng/mL at LT (P < 0.001). In multivariable analysis, a decrease in the AFP to 101-499 ng/mL was associated with a > 2-fold reduction in posttransplant mortality (P = 0.01) and a nearly 3-fold reduction in HCC recurrence (P = 0.02) compared with AFP > 1,000 ng/mL at LT. Conclusion: Our results demonstrated significantly improved post-LT outcomes when restricting LT to patients with a reduction in AFP from > 1,000 to < 500 ng/mL, validating the recently implemented national policy.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Mehta N, Dodge JL, Roberts JP, et al. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology. 2019. PMID: 30548884. doi:10.1002/hep.30413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。